BLA 761430 · Janssen Biotech
Imaavy
Nipocalimab-Aahu · Injection
NovelPriority reviewOrphanCDER novel approval, Apr 29, 2025: To treat generalized myasthenia gravis
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Apr 29, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
21
10 Phase 3, 9 recruiting
FAERS reports
318
119 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 21, 2026.
IMAAVY is a neonatal Fc receptor blocker indicated for the treatment of: generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. ( 1.1 ) warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. ( 1.2 ) 1.1 Generalized Myasthenia Gravis (gMG) IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. 1.2 Warm Autoimmune Hemolytic Anemia (wAIHA) IMAAVY is indicated for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids.
Mechanism: Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 24, 2026 Supplement 2 · Efficacy · priority review OrphanLabelLetter
- Apr 29, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- IMAAVY · NIPOCALIMAB-AAHU 1200MG/6.5ML(185MG/ML) · INJECTABLE, INJECTION · Prescription
- IMAAVY · NIPOCALIMAB-AAHU 300MG/1.62ML(185MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nipocalimab" as an intervention, any sponsor and status, largest first.
- Nipocalimab in Moderate to Severe Sjogren's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06741969 · 655 participants · Start Dec 4, 2024 · Primary completion Feb 4, 2027
Drug: Nipocalimab; Placebo and 1 more · For: Sjogrens Syndrome
Sites: Chula Vista, California; La Palma, California; Mission Viejo, California · 254 sites in all
- A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07438496 · 600 participants (planned) · Start Mar 5, 2026 · Primary completion Dec 6, 2028
Drug: Nipocalimab; Placebo and 1 more · For: Lupus Erythematosus, Systemic
Sites: Beverly Hills, California; Hemet, California; La Palma, California · 272 sites in all
- A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04882878 · 228 participants · Start Aug 20, 2021 · Primary completion Apr 30, 2024
Drug: Nipocalimab; Standard-of-care treatment · For: Systemic Lupus Erythematosus
Sites: Los Alamitos, California; Rancho Mirage, California; Santa Ana, California · 86 sites in all
- Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05327114 · 201 participants (planned) · Start Sep 23, 2022 · Primary completion Dec 15, 2026
Drug: Nipocalimab; Placebo · For: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Sites: Centennial, Colorado; Coral Springs, Florida; Maitland, Florida · 120 sites in all
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04951622 · 199 participants (planned) · Start Jul 15, 2021 · Primary completion Nov 17, 2023
Drug: Nipocalimab; Placebo and 1 more · For: Myasthenia Gravis
Sites: Paradise Valley, Arizona; Scottsdale, Arizona; Los Angeles, California · 112 sites in all
- A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04968912 · 163 participants · Start Sep 21, 2021 · Primary completion Oct 23, 2023
Drug: Nipocalimab; Standard of Care Treatment · For: Sjogren's Syndrome
Sites: Anniston, Alabama; Glendale, Arizona; Mesa, Arizona · 69 sites in all
- A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05912517 · 120 participants (planned) · Start Dec 20, 2023 · Primary completion Aug 5, 2027
Drug: Nipocalimab; Placebo · For: Hemolytic Disease of the Fetus and Newborn
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 69 sites in all
- Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic AnemiaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04119050 · 118 participants · Start Aug 15, 2019 · Primary completion Feb 2, 2025
Drug: M281; Placebo · For: Warm Autoimmune Hemolytic Anemia
Sites: Fountain Valley, California; Los Angeles, California; Riverside, California · 171 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective30
- myasthenia gravis25
- headache20
- oedema peripheral20
- fatigue18
- dyspnoea16
- influenza14
- off label use14
- product dose omission issue13
- infusion related reaction11
- rash11
- therapeutic response decreased11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 88 |
| 2026 | 230 |
Recalls
1 FDA enforcement reports for this application.
Sep 23, 2026 · Class II · Ongoing
Presence of particulate matter.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Antozzi C, Vu T, Ramchandren S, et al. · Lancet Neurol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Nipocalimab Dose Selection in Generalized Myasthenia Gravis.
Valenzuela B, Neyens M, Zhu Y, et al. · CPT Pharmacometrics Syst Pharmacol 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn.
Moise KJ, Ling LE, Oepkes D, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Multicenter Study
- Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Antozzi C, Guptill J, Bril V, et al. · Neurology 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.
Taylor PC, Schett G, Huizinga TW, et al. · RMD Open 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and metaߛanalysis.
Akhtar M, Akhtar M, Farooqi HA, et al. · Clin Neurol Neurosurg 2025 · Systematic Review, Meta-Analysis
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.